Aim: The aim was to evaluate if smoking was a risk factor for proliferative retinopathy (PDR) in a 25-year follow-up study. Methods: 201 persons from a population-based cohort of Danish type 1 diabetic patients were examined at baseline and again 25 years later. At both examinations the patients were asked about their smoking habits. The level of retinopathy was evaluated by ophthalmoscopy at baseline and by nine 45-degree colour field fundus photos at the follow-up. Results: In multivariate analyses there was a trend that current smokers at baseline were more likely to develop PDR at the follow-up (odds ratio 1.90, 95% confidence interval 0.88-4.11, p = 0.10). Neither smoking status at the follow-up nor pack-years of smoking were associated with PDR. Conclusions: We found neither a beneficial nor a harmful effect of smoking on long-term incidence. Selective mortality among smokers and patients with PDR at baseline might provide at least part of the explanation for this.

Keywords:
Proliferative diabetic retinopathy, Diabetes mellitus, Smoking
1.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526.
2.
Grauslund J, Green A, Sjolie AK: Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients. Diabetologia 2009;52:1829-1835.
3.
Grauslund J, Green A, Sjolie AK: Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients. Ophthalmology 2009;116:2170-2174.
4.
Klein R, Klein BE: Vision Disorders in Diabetes. Diabetes in America, ed 2. Bethesda, National Institutes of Health, 1995, pp 1-36.
5.
The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
6.
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XXII. The twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115:1859-1868.
7.
Eliasson B: Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003;45:405-413.
8.
Chaturvedi N, Stephenson JM, Fuller JH: The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care 1995;18:785-792.
9.
Karamanos B, Porta M, Songini M, Metelko Z, Kerenyi Z, Tamas G, Rottiers R, Stevens LK, Fuller JH: Different risk factors of microangiopathy in patients with type I diabetes mellitus of short versus long duration. The EURODIAB IDDM Complications Study. Diabetologia 2000;43:348-355.
10.
Larsson LI, Alm A, Bergenheim T, Lithner F, Bergstrom R: Retinopathy in diabetic patients aged 15-50 years in the county of Umea, Sweden. Acta Ophthalmol Scand 1999;77:430-436.
11.
Muhlhauser I, Bender R, Bott U, Jorgens V, Grusser M, Wagener W, Overmann H, Berger M: Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 1996;13:536-543.
12.
Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM: Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 2001;24:284-289.
13.
Klein R, Klein BE, Davis MD: Is cigarette smoking associated with diabetic retinopathy? Am J Epidemiol 1983;118:228-238.
14.
Moss SE, Klein R, Klein BE: Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996;103:1438-1442.
15.
Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T: Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med Scand 1984;215:63-68.
16.
Moss SE, Klein R, Klein BE: Association of cigarette smoking with diabetic retinopathy. Diabetes Care 1991;14:119-126.
17.
Klein R, Klein BE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-1815.
18.
Green A, Hauge M, Holm NV, Rasch LL: Epidemiological studies of diabetes mellitus in Denmark. II. A prevalence study based on insulin prescriptions. Diabetologia 1981;20:468-470.
19.
Sjolie AK: Ocular complications in insulin treated diabetes mellitus. An epidemiological study. Acta Ophthalmol Suppl 1985;172:1-77.
20.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989;107:237-243.
21.
Klein R, Klein BE, Magli YL, Brothers RJ, Meuer SM, Moss SE, Davis MD: An alternative method of grading diabetic retinopathy. Ophthalmology 1986;93:1183-1187.
22.
Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991;98:786-806.
23.
Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98:823-833.
24.
Klein BE, Davis MD, Segal P, Long JA, Harris WA, Haug GA, Magli YL, Syrjala S: Diabetic retinopathy. Assessment of severity and progression. Ophthalmology 1984;91:10-17.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.